Immutep Ltd ADR (NASDAQ:IMMP) — Market Cap & Net Worth
Market Cap & Net Worth: Immutep Ltd ADR (IMMP)
Immutep Ltd ADR (NASDAQ:IMMP) has a market capitalization of $84.03 Million ($84.03 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19943 globally and #4480 in its home market, demonstrating a 4.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immutep Ltd ADR's stock price $0.57 by its total outstanding shares 147192034 (147.19 Million). Review IMMP total debt and obligations to assess the company's total debt and financial obligations.
Immutep Ltd ADR Market Cap History: 2015 to 2026
Immutep Ltd ADR's market capitalization history from 2015 to 2026. Data shows change from $559.33 Million to $55.04 Million (-17.28% CAGR).
Index Memberships
Immutep Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #564 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1922 of 3165 |
Weight: Immutep Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immutep Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immutep Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
83.46x
Immutep Ltd ADR's market cap is 83.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $344.43 Million | $175.05K | -$62.02 Million | 1967.58x | N/A |
| 2017 | $231.09 Million | $4.22 Million | -$9.37 Million | 54.74x | N/A |
| 2018 | $270.83 Million | $2.63 Million | -$12.75 Million | 102.96x | N/A |
| 2019 | $263.47 Million | $139.78K | -$16.27 Million | 1884.89x | N/A |
| 2020 | $462.18 Million | $7.49 Million | -$13.47 Million | 61.74x | N/A |
| 2021 | $482.79 Million | $3.86 Million | -$29.90 Million | 124.98x | N/A |
| 2022 | $257.59 Million | $170.37K | -$32.21 Million | 1511.93x | N/A |
| 2023 | $353.26 Million | $3.51 Million | -$39.90 Million | 100.77x | N/A |
| 2024 | $319.41 Million | $3.84 Million | -$42.72 Million | 83.14x | N/A |
| 2025 | $420.97 Million | $5.04 Million | -$61.43 Million | 83.46x | N/A |
Competitor Companies of IMMP by Market Capitalization
Companies near Immutep Ltd ADR in the global market cap rankings as of June 19, 2026.
Key companies related to Immutep Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Immutep Ltd ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Immutep Ltd ADR's market cap moved from $559.33 Million to $ 55.04 Million, with a yearly change of -17.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $55.04 Million | -86.93% |
| 2025 | $420.97 Million | +31.80% |
| 2024 | $319.41 Million | -9.58% |
| 2023 | $353.26 Million | +37.14% |
| 2022 | $257.59 Million | -46.65% |
| 2021 | $482.79 Million | +4.46% |
| 2020 | $462.18 Million | +75.42% |
| 2019 | $263.47 Million | -2.72% |
| 2018 | $270.83 Million | +17.20% |
| 2017 | $231.09 Million | -32.91% |
| 2016 | $344.43 Million | -38.42% |
| 2015 | $559.33 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Immutep Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.03 Million USD |
| MoneyControl | $84.03 Million USD |
| MarketWatch | $84.03 Million USD |
| marketcap.company | $84.03 Million USD |
| Reuters | $84.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more